INSBANK Parent InsCorp Reports Second Quarter Results, Declares Quarterly Cash Dividend, and Authorizes Share Repurchase
InsCorp, Inc. reported net income of $1,820,000, or $0.63 per share, in Q2 2024, up from $1,763,000 in Q1 2024. The company achieved a ROAE of 10.1% and operating EPS of $0.65. Loan originations increased to $57 million in Q2, up from $23 million in Q1, with strength in Medquity, CRE, C&D, and C&I loans. The loan pipeline grew to $79 million. Medquity reported 9% Y/Y loan growth. Revenue declined 1.1% Y/Y but improved 2.7% LQA to $6,212,000. The net interest margin was 3.08%. Asset quality remains healthy with no net chargeoffs. InsCorp's Board authorized a share repurchase of 125,000 shares and declared a quarterly dividend of $0.10 per share.
InsCorp, Inc. ha riportato un utile netto di 1.820.000 dollari, ovvero 0,63 dollari per azione, nel secondo trimestre del 2024, rispetto a 1.763.000 dollari nel primo trimestre del 2024. L'azienda ha registrato un ROAE del 10,1% e un EPS operativo di 0,65 dollari. Le origini dei prestiti sono aumentate a 57 milioni di dollari nel secondo trimestre, rispetto a 23 milioni di dollari nel primo trimestre, con punti di forza nei prestiti Medquity, CRE, C&D e C&I. Il portafoglio prestiti è cresciuto a 79 milioni di dollari. Medquity ha riportato una crescita dei prestiti del 9% rispetto all'anno precedente. I ricavi sono diminuiti dell'1,1% anno su anno ma sono migliorati del 2,7% rispetto all'ultimo trimestre a 6.212.000 dollari. Il margine d'interesse netto era del 3,08%. La qualità delle attività rimane sana senza addebiti netti. Il Consiglio di InsCorp ha autorizzato un riacquisto di azioni di 125.000 azioni e ha dichiarato un dividendo trimestrale di 0,10 dollari per azione.
InsCorp, Inc. reportó un ingreso neto de 1.820.000 dólares, o 0,63 dólares por acción, en el segundo trimestre de 2024, un aumento respecto a 1.763.000 dólares en el primer trimestre de 2024. La compañía logró un ROAE del 10,1% y un EPS operativo de 0,65 dólares. Las originaciones de préstamos aumentaron a 57 millones de dólares en el segundo trimestre, subiendo desde 23 millones de dólares en el primer trimestre, con fortaleza en préstamos Medquity, CRE, C&D y C&I. El pipeline de préstamos creció a 79 millones de dólares. Medquity reportó un crecimiento de préstamos del 9% interanual. Los ingresos disminuyeron un 1,1% interanual, pero mejoraron un 2,7% en comparación con el último trimestre, alcanzando 6.212.000 dólares. El margen de interés neto fue del 3,08%. La calidad de los activos se mantiene saludable sin cargos netos. La Junta de InsCorp autorizó un recompra de acciones de 125.000 acciones y declaró un dividendo trimestral de 0,10 dólares por acción.
InsCorp, Inc.는 2024년 2분기에 1,820,000달러의 순이익, 즉 주당 0.63달러를 기록했으며, 이는 2024년 1분기의 1,763,000달러에서 증가한 수치입니다. 회사는 10.1%의 ROAE와 0.65달러의 운영 EPS를 달성했습니다. 대출 발행량은 2분기에 5,700만 달러로 증가했으며, 이는 1분기의 2,300만 달러에서 상승한 것입니다. Medquity, CRE, C&D, C&I 대출에서 강세를 보였습니다. 대출 파이프라인은 7,900만 달러로 성장했습니다. Medquity는 전년 대비 9%의 대출 성장을 보고했습니다. 연간 수익은 1.1% 감소했지만, 전 분기 대비 2.7% 증가하여 6,212,000달러에 달했습니다. 순이자 마진은 3.08%였습니다. 자산의 질은 건강하며, 순손실은 없습니다. InsCorp의 이사회는 125,000주의 자사주 매입을 승인하고, 주당 0.10달러의 분기 배당금을 선언했습니다.
InsCorp, Inc. a rapporté un revenu net de 1.820.000 dollars, soit 0,63 dollars par action, au 2ème trimestre 2024, en hausse par rapport à 1.763.000 dollars au 1er trimestre 2024. La société a atteint un ROAE de 10,1% et un EPS opérationnel de 0,65 dollars. Les origines de prêts ont augmenté à 57 millions de dollars au 2ème trimestre, contre 23 millions de dollars au 1er trimestre, avec des performances solides dans les prêts Medquity, CRE, C&D et C&I. Le pipeline de prêts a crû à 79 millions de dollars. Medquity a rapporté une croissance des prêts de 9 % d'une année sur l'autre. Les revenus ont diminué de 1,1 % d'une année sur l'autre mais ont augmenté de 2,7 % par rapport au dernier trimestre, atteignant 6.212.000 dollars. La marge d'intérêt nette était de 3,08%. La qualité des actifs reste saine sans annulations nettes. Le conseil d'administration d'InsCorp a autorisé un rachat de 125.000 actions et a déclaré un dividende trimestriel de 0,10 dollars par action.
InsCorp, Inc. berichtete über einen Nettoertrag von 1.820.000 US-Dollar, also 0,63 US-Dollar pro Aktie, im 2. Quartal 2024, ein Anstieg von 1.763.000 US-Dollar im 1. Quartal 2024. Das Unternehmen erzielte eine ROAE von 10,1% und ein operatives EPS von 0,65 US-Dollar. Die Kreditvergaben stiegen im 2. Quartal auf 57 Millionen US-Dollar, gegenüber 23 Millionen US-Dollar im 1. Quartal, mit starken Ergebnissen in den Bereichen Medquity, CRE, C&D und C&I Kredite. Die Kreditpipeline wuchs auf 79 Millionen US-Dollar. Medquity meldete ein Kreditwachstum von 9% im Jahresvergleich. Der Umsatz sank im Jahresvergleich um 1,1%, verbesserte sich jedoch im Vergleich zum letzten Quartal um 2,7% auf 6.212.000 US-Dollar. Die Nettomarge betrug 3,08%. Die Asset-Qualität bleibt gesund ohne Nettobelastungen. Der Vorstand von InsCorp genehmigte einen Aktienrückkauf von 125.000 Aktien und erklärte eine Quartalsdividende von 0,10 US-Dollar pro Aktie.
- Net income increased to $1,820,000 in Q2 2024, up from $1,763,000 in Q1 2024
- Loan originations grew to $57 million in Q2 2024, up from $23 million in Q1 2024
- Loan pipeline increased to $79 million, up from $67 million a quarter ago
- Medquity segment reported 9% Y/Y loan growth
- Noninterest income grew 37% Y/Y to $590,000 in Q2 2024
- Net interest margin improved to 3.08% in Q2 2024 from 2.94% in Q1 2024
- Board authorized share repurchase of 125,000 shares (4.3% of outstanding shares)
- Declared quarterly dividend of $0.10 per share, a 17.6% annualized increase from 2023
- Revenue declined 1.1% Y/Y to $6,212,000 in Q2 2024
- Net interest income declined 4% Y/Y to $5,622,000
- Expense growth of 5% Y/Y to $3,676,000
- Cost of deposits increased 88 basis points Y/Y to 3.89% in Q2 2024
- Nonperforming assets increased to 1.08% of loans from 0.18% a year ago
NASHVILLE, Tenn., Aug. 2, 2024 /PRNewswire/ -- InsCorp, Inc. reported net income of
Excluding gains and losses from hedging activities, operating EPS of
Bank-wide loan originations continued to gain momentum—increasing to
Given a resumption of loan growth to
Medquity, INSBANK's healthcare business, continues to provide solid growth and diversification given its national focus and reduced sensitivity to economic and real estate cycles. In 2Q24, Medquity reported loan growth of
"Our team had one of its best-ever quarters for new commercial deposit accounts, and the growth in noninterest bearing deposits reflects that activity," Rieniets stated. "As we have methodically focused on treasury resources in recent years, we're pleased to report both balance expansion in operating accounts as well as double-digit fee income growth on an annualized basis." Customer rationalization of low-cost deposits into a combination of higher yielding CDs, loan payoffs, and business investment has adversely affected INSBANK's deposit mix over the past two years. Importantly, demand deposit balances (noninterest bearing and interest bearing) increased
Revenue declined
The bank-level net interest margin of
Asset quality measures remain healthy. Net chargeoffs represented
Nonperforming assets were
Although the aggregate level of watch list loans increased slightly compared to the prior quarter-end, the balance decreased approximately
C&D and CRE concentration levels remain below regulatory guidance and historically normal levels. Specifically, C&D increased +
Measures of liquidity risk remain healthy and remain adequate to fund loan growth over the near-term. Specifically, balance sheet liquidity ended 2Q24 at
Tangible book value increased
"With healthy equity ratios, internally generated capital of roughly
About INSBANK
Since 2000, INSBANK has offered its clients highly personalized service provided by experienced relationship managers, while positioning itself as an innovator, utilizing technologies to deliver those services efficiently and conveniently. In addition to its commercial focused operation, INSBANK operates through three divisions, Medquity, TMA Medical Banking and Finworth. Medquity offers healthcare banking solutions to physicians, partnerships, and practices nationwide, while TMA Medical Banking provides banking services specifically to members of the Tennessee Medical Association. Finworth offers nationally available virtual private client services for interest bearing deposits. INSBANK is owned by InsCorp, Inc., a
InsCorp, Inc. | |||||
Consolidated Balance Sheets | |||||
(000's) | |||||
(unaudited) | |||||
June 30, | December 31, | June 30, | |||
2024 | 2023 | 2023 | |||
Assets | |||||
Cash and Cash Equivalents | $ 5,203 | $ 7,688 | $ 4,237 | ||
Interest Bearing Deposits | 47,383 | 49,757 | 39,416 | ||
Securities | 56,056 | 58,162 | 53,264 | ||
Loans | 684,533 | 681,558 | 675,627 | ||
Allowance for Credit Losses | (9,216) | (9,126) | (9,536) | ||
Net Loans | 675,317 | 672,432 | 666,091 | ||
Premises and Equipment, net | 12,568 | 12,715 | 12,879 | ||
Bank Owned Life Insurance | 14,257 | 14,065 | 13,888 | ||
Restricted Equity Securities | 9,379 | 8,890 | 8,758 | ||
Goodwill and Related Intangibles, net | 1,091 | 1,091 | 1,091 | ||
Other Assets | 13,082 | 12,290 | 13,904 | ||
Total Assets | $ 834,336 | $ 837,090 | $ 813,528 | ||
Liabilities and Shareholders' Equity | |||||
Liabilities | |||||
Deposits | |||||
$ 76,417 | $ 70,417 | $ 75,624 | |||
600,949 | 615,779 | 580,025 | |||
677,366 | 686,196 | 655,649 | |||
Federal Home Loan Bank Advances | 45,000 | 45,000 | 58,000 | ||
Subordinated Debentures | 17,360 | 17,348 | 17,500 | ||
Notes Payable | 8,516 | 8,750 | 8,250 | ||
Other Liabilities | 13,283 | 9,939 | 7,182 | ||
Total Liabilities | 761,525 | 767,233 | 746,581 | ||
Shareholders' Equity | |||||
Common Stock | 33,426 | 33,112 | 32,906 | ||
Treasury Stock | (3,882) | (3,869) | (3,857) | ||
Accumulated Retained Earnings | 44,704 | 41,714 | 37,633 | ||
Accumulated Other Comprehensive Income | (1,437) | (1,100) | 265 | ||
Total Stockholders' Equity | 72,811 | 69,857 | 66,947 | ||
Total Liabilities & Shareholders' Equity | $ 834,336 | $ 837,090 | $ 813,528 | ||
Tangible Book Value | $ 24.89 | $ 23.93 | $ 22.35 |
InsCorp, Inc. | |||||||||
Consolidated Statements of Income | |||||||||
(000's) | |||||||||
(Unaudited) | |||||||||
Three Months Ended | Six Months Ended | ||||||||
June 30, 2024 | March 31, 2024 | June 30, 2023 | June 30, 2024 | June 30, 2023 | |||||
Interest Income | $ 12,696 | $ 12,563 | $ 11,548 | $ 25,259 | $ 21,934 | ||||
Interest Expense | 7,074 | 6,970 | 5,694 | 14,044 | 10,308 | ||||
Net Interest Income | 5,622 | 5,593 | 5,854 | 11,215 | 11,626 | ||||
Provision for Credit Losses | 75 | 25 | 140 | 100 | 265 | ||||
Noninterest Income | |||||||||
Service Charges on Deposit Accounts | 71 | 67 | 51 | 138 | 98 | ||||
Bank Owned Life Insurance | 97 | 95 | 85 | 192 | 167 | ||||
Other | 422 | 415 | 294 | 837 | 592 | ||||
Noninterest Expense | |||||||||
Salaries and Benefits | 2,395 | 2,301 | 2,232 | 4,696 | 4,483 | ||||
Occupancy and equipment | 422 | 393 | 374 | 815 | 747 | ||||
Data Processing | 101 | 94 | 116 | 195 | 215 | ||||
Marketing and Advertising | 71 | 119 | 160 | 190 | 276 | ||||
Other | 687 | 652 | 616 | 1,339 | 1,237 | ||||
Net Income from Operations | 2,461 | 2,586 | 2,646 | 5,047 | 5,260 | ||||
Gain (Loss) in Interest Rate Hedges | (93) | (252) | (304) | (345) | (238) | ||||
Income Before Income Taxes | 2,368 | 2,334 | 2,342 | 4,702 | 5,022 | ||||
Income Tax Expense | (548) | (571) | (566) | (1,119) | (1,196) | ||||
Net Income | $ 1,820 | $ 1,763 | $ 1,776 | $ 3,583 | $ 3,826 | ||||
Earnings per Share | $ 0.63 | $ 0.61 | $ 0.62 | $ 1.24 | $ 1.33 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/insbank-parent-inscorp-reports-second-quarter-results-declares-quarterly-cash-dividend-and-authorizes-share-repurchase-302213792.html
SOURCE INSBANK
FAQ
What was InsCorp's (IBTN) net income for Q2 2024?
How much did InsCorp's (IBTN) loan originations increase in Q2 2024?
What was InsCorp's (IBTN) net interest margin in Q2 2024?
How many shares did InsCorp (IBTN) authorize for repurchase in August 2024?